Search results
4 kwi 2022 · Overall, targeting mutations in tyrosine kinases has been a fruitful therapeutic strategy: BCR-ABL inhibitors have transformed treatment of CML, and both mAbs and TKIs are standard-of-care for EGFR -mutant NSCLC and HER2-positive BC.
- Cancer Therapy Guided by Mutation Tests: Current Status and ...
Treatment planning for non-small cell lung cancer requires...
- The Current Status of Gene Therapy for the Treatment of Cancer
Cancer occurs due to disrupting the normal cell...
- Cancer Therapy Guided by Mutation Tests: Current Status and ...
7 sie 2023 · The genetic mutations that contribute to the transformation of healthy cells into cancerous cells have been the subject of extensive research. The molecular aberrations that lead to cancer...
10 paź 2021 · Treatment planning for non-small cell lung cancer requires testing for EGFR, ALK, ROS1, BRAF, MET, RET and KRAS gene alterations. Colorectal cancer patients need to undergo KRAS, NRAS, BRAF, HER2 and microsatellite instability analysis.
18 mar 2021 · Cancer occurs due to disrupting the normal cell proliferation and apoptosis process. Advances in cancer therapy need a novel therapeutic agent with novel mode of action, several mechanisms of cell death, and synergy with conventional management. Gene therapies possess all these profiles.
17 lip 2024 · Currently, popular tumor cell therapies include Chimeric Antigen Receptor T-Cell Therapy (CAR-T), T-Cell Receptor Modified T cells (TCR-T), Tumor-Infiltrating Lymphocytes (TIL), Chimeric...
18 lis 2020 · Genomic instability and mutations underlie the hallmarks of cancer—genetic alterations determine cancer cell fate by affecting cell proliferation, apoptosis and immune response, and...
28 wrz 2021 · The synthetic lethality-based approach targeting mutp53, such as utilizing PARP inhibitors to treat cancers harboring BRCA1/2 mutations, can kill tumors with mutp53 while having no or little negative effects on normal cells or tissues.
